Pure Biologics Spólka Akcyjna (PLN) Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise, concentrating its efforts on the discovery and development of novel biological pharmaceuticals and targeted, non-systemic treatments. The company's key therapeutic interests span immuno-oncology, various autoimmune conditions, and rare diseases. Its capabilities encompass the entire process for antibodies and aptamers, from their initial creation and purification to detailed analysis and characterization. Additionally, Pure Biologics is skilled in the design, development, and rigorous validation of diagnostic and research assays, while also advancing technology platforms for the precise selection of active therapeutic molecules. A significant offering is PureApta, a adaptable platform engineered for the in vitro selection of modified aptamers, suitable for both medical treatment and diagnostic applications. The firm is also actively pursuing the development of localized therapies aimed at assisting individuals afflicted by neurological autoimmune disorders, including conditions like neuromyelitis optica and myasthenia gravis. Founded in 2010, Pure Biologics Spólka Akcyjna is headquartered in Wroclaw, Poland.

Pure Biologics Spólka Akcyjna (PLN) Active

Szczytnicka 11, Wroclaw, DS, PL, 54-427

Stock Price PLN

Price Change

Last Dividend PLN

Latest Rating

PUR.WA's stock peer is ADV.WA (Adiuvo Investments S.A.)

PUR.WA's stock peer is AWM.WA (Airway Medix S.A.)

PUR.WA's stock peer is BMX.WA (BioMaxima S.A.)

PUR.WA's stock peer is GMT.WA (Genomtec S.A.)

PUR.WA's stock peer is MAB.WA (Mabion S.A.)

PUR.WA's stock peer is MOC.WA (Molecure S.A.)

PUR.WA's stock peer is NNG.WA (NanoGroup S.A.)

PUR.WA's stock peer is PHR.WA (Pharmena S.a.)

PUR.WA's stock peer is PTG.WA (Poltreg S.A.)

PUR.WA's stock peer is URT.WA (Urteste S.A.)

Healthcare Biotechnology

Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise, concentrating its efforts on the discovery and development of novel biological pharmaceuticals and targeted, non-systemic treatments. The company's key therapeutic interests span immuno-oncology, various autoimmune conditions, and rare diseases. Its capabilities encompass the entire process for antibodies and aptamers, from their initial creation and purification to detailed analysis and characterization. Additionally, Pure Biologics is skilled in the design, development, and rigorous validation of diagnostic and research assays, while also advancing technology platforms for the precise selection of active therapeutic molecules. A significant offering is PureApta, a adaptable platform engineered for the in vitro selection of modified aptamers, suitable for both medical treatment and diagnostic applications. The firm is also actively pursuing the development of localized therapies aimed at assisting individuals afflicted by neurological autoimmune disorders, including conditions like neuromyelitis optica and myasthenia gravis. Founded in 2010, Pure Biologics Spólka Akcyjna is headquartered in Wroclaw, Poland.

20%

Dcf Rating

100%

Return On Equity

20%

Return On Assets

20%

Debt To Equity

20%

Price To Earnings

20%

Price To Book

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions